Hims & Hers health chief legal officer sells $89,863 in stock

SAN FRANCISCO—Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold a portion of the company’s Class A Common Stock, according to a filing with the Securities and Exchange Commission. The transaction, which took place on March 31, 2025, involved the sale of 3,236 shares at an average price of $27.77 each, totaling approximately $89,863.

Following this transaction, Soleil retains direct ownership of 170,285 shares in the company. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted on August 28, 2024. This type of plan allows company insiders to sell a predetermined number of shares at a set time to avoid any potential accusations of insider trading. Despite recent market volatility causing a 20% decline in the past week, InvestingPro analysis indicates the company maintains a "GREAT" financial health score.

Hims & Hers Health, known for its telehealth services, continues to be a notable player in the healthcare sector. Investors often closely monitor insider transactions as they can provide insights into the company’s prospects and the executives’ confidence in its future performance.

In other recent news, Hims & Hers Health announced its expansion into offering Eli Lilly (NYSE:LLY)’s diabetes and weight-loss drug, Zepbound, on its telehealth platform. This move is part of a broader strategy to enhance its pharmaceutical offerings by including both branded and generic versions of significant drugs, such as generic liraglutide, a diabetes medication. Despite the positive reception from investors, BofA Securities maintained an Underperform rating on Hims & Hers, with a price target of $22.00. Analyst Michael Cherny indicated that while the sales of Zepbound are unlikely to significantly impact Hims & Hers’ financial results, the addition of generic liraglutide could prove more relevant.

Sales data from Bloomberg Second Measure highlighted a 124% year-over-year growth in GLP-1 sales, which are now a major part of the company’s online revenue. This data suggests a potential upside to Street estimates, with projected first-quarter online revenue for 2025 ranging from $594 million to $622 million. However, BofA Securities noted a deceleration in core growth, with first-quarter growth potentially at 30%, down from previous quarters. Semaglutide, a key component in weight management, currently accounts for nearly half of Hims & Hers’ sales, presenting a risk if removed from the sales model. Despite these developments, the revised price target remains based on a 17 times multiple of the company’s projected CY25E EV/EBITDA.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.